BR112016030183A2 - anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos - Google Patents

anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos

Info

Publication number
BR112016030183A2
BR112016030183A2 BR112016030183A BR112016030183A BR112016030183A2 BR 112016030183 A2 BR112016030183 A2 BR 112016030183A2 BR 112016030183 A BR112016030183 A BR 112016030183A BR 112016030183 A BR112016030183 A BR 112016030183A BR 112016030183 A2 BR112016030183 A2 BR 112016030183A2
Authority
BR
Brazil
Prior art keywords
antibodies
microtubule
antigen binding
specifically bind
binding fragments
Prior art date
Application number
BR112016030183A
Other languages
English (en)
Inventor
Pascual Gabriel
Goudsmit Jaap
Wadia Jehangir
Radosevic Katarina
Anthony Williamson Robert
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of BR112016030183A2 publication Critical patent/BR112016030183A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Abstract

a invenção se refere a anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos. a invenção também se refere a métodos de diagnóstico, profiláticos e terapêuticos utilizando anticorpos anti-tau.
BR112016030183A 2014-06-26 2015-06-26 anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos BR112016030183A2 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462017789P 2014-06-26 2014-06-26
US201462017807P 2014-06-26 2014-06-26
US201462017746P 2014-06-26 2014-06-26
US201462017812P 2014-06-26 2014-06-26
EP14179719 2014-08-04
EP14179706 2014-08-04
EP14179699 2014-08-04
EP14179739 2014-08-04
PCT/EP2015/064533 WO2015197823A2 (en) 2014-06-26 2015-06-26 Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau

Publications (1)

Publication Number Publication Date
BR112016030183A2 true BR112016030183A2 (pt) 2017-11-14

Family

ID=54937409

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112016030183A BR112016030183A2 (pt) 2014-06-26 2015-06-26 anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos
BR112016029579A BR112016029579A2 (pt) 2014-06-26 2015-06-26 anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112016029579A BR112016029579A2 (pt) 2014-06-26 2015-06-26 anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos

Country Status (13)

Country Link
US (2) US10400034B2 (pt)
EP (3) EP3160998B1 (pt)
JP (2) JP2017521063A (pt)
KR (2) KR20170023124A (pt)
CN (2) CN107074965B (pt)
AU (3) AU2015279086B2 (pt)
BR (2) BR112016030183A2 (pt)
CA (2) CA2952745A1 (pt)
EA (2) EA036307B1 (pt)
NZ (2) NZ727024A (pt)
SG (2) SG11201610459XA (pt)
WO (2) WO2015197820A1 (pt)
ZA (1) ZA201608811B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201707855YA (en) 2013-03-13 2017-10-30 Prothena Biosciences Ltd Tau immunotherapy
WO2015197820A1 (en) * 2014-06-26 2015-12-30 Crucell Holland B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
PE20190261A1 (es) 2016-05-02 2019-02-25 Prothena Biosciences Ltd Anticuerpos que reconocen tau
CN109415432B (zh) 2016-05-02 2022-07-08 普罗塞纳生物科学有限公司 Tau免疫疗法
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
MA47499A (fr) 2017-02-17 2019-12-25 Denali Therapeutics Inc Anticorps anti-tau et leurs procédés d'utilisation
CN110418804A (zh) * 2017-03-28 2019-11-05 扬森疫苗与预防公司 与tau特异性地结合的结合分子
WO2018195376A1 (en) * 2017-04-21 2018-10-25 Ohio University Peptide-based inhibitors of mark family proteins
BR112019022906A2 (pt) 2017-05-02 2020-05-26 Prothena Biosciences Limited Anticorpos que reconhecem tau
JP6851549B2 (ja) 2017-10-16 2021-03-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗タウ抗体及びその使用
JP2021501147A (ja) * 2017-10-25 2021-01-14 ヤンセン ファーマシューティカルズ，インコーポレーテッド リン酸化タウペプチドの組成物およびその使用
US20200369754A1 (en) * 2017-12-04 2020-11-26 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
WO2019133799A1 (en) * 2017-12-29 2019-07-04 University Of Florida Research Foundation Monoclonal antibodies targeting microtubule-binding domain of tau protein
EA202091756A1 (ru) * 2018-02-01 2020-10-28 Янссен Вэксинс Энд Превеншн Б.В. Связывающие молекулы, специфично связывающиеся с тау-белком
CN112105639A (zh) * 2018-03-05 2020-12-18 詹森药业有限公司 抗PHF-tau抗体及其用途
US20200408781A1 (en) 2018-03-05 2020-12-31 Gallen Triana-Baltzer Assays to detect neurodegeneration
EP3774889A4 (en) * 2018-03-11 2021-12-08 Koorosh Shahpasand CONFORMITY INDEPENDENT ANTIBODIES AGAINST NEUROTOXIC TAU PROTEINS
US20210347868A1 (en) * 2018-10-19 2021-11-11 Gabriel Pascual Anti-synuclein antibodies
EA202192203A1 (ru) 2019-02-08 2021-10-20 Ац Иммуне С.А. СПОСОБ БЕЗОПАСНОГО ВВЕДЕНИЯ ВАКЦИНЫ ФОСФОРИЛИРОВАННОГО ПЕПТИДА Tau
CU20210073A7 (es) 2019-03-03 2022-04-07 Prothena Biosciences Ltd Anticuerpos que se unen dentro de la región de unión a microtúbulos de tau definida por cdrs
CN114173812A (zh) 2019-04-24 2022-03-11 杨森制药公司 Tau疫苗的异源给予
GB2585252A (en) 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
GB9316727D0 (en) * 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease
US5585250A (en) 1993-08-20 1996-12-17 The United States Of America As Represented By The Department Of Health & Human Services Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies
KR100483498B1 (ko) 1996-02-14 2005-07-18 악조 노벨 엔.브이. 핵산물질의분리및증폭방법
JP3689333B2 (ja) 1997-08-08 2005-08-31 アクゾ・ノベル・エヌ・ベー Ｈｉｖ−１の全てのサブタイプを増幅及び検出するためにプライマー及びプローブとして使用できる核酸配列
US6531313B1 (en) 1999-10-26 2003-03-11 International Aids Vaccine Initiative Invasive bacterial vectors for expressing alphavirus replicons
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
US20050019759A1 (en) 2000-09-08 2005-01-27 Jaap Goudsmit Attenuated HIV strains and uses thereof
US20030008275A1 (en) 2000-09-08 2003-01-09 Jaap Goudsmit Attenuated HIV strains and use thereof
WO2003017918A2 (en) * 2001-08-24 2003-03-06 Universität Zürich A method of inducing the formation of neurofibrillary tangles in transgenic animals
EP1633775A2 (en) 2003-06-13 2006-03-15 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
WO2005084158A2 (en) 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
WO2005012337A2 (en) 2003-07-15 2005-02-10 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
EP1646645A1 (en) 2003-07-21 2006-04-19 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
CA2531684C (en) 2003-07-22 2014-03-11 Crucell Holland B.V. Binding molecules against sars-coronavirus and uses thereof
AU2004270409A1 (en) 2003-09-04 2005-03-17 Crucell Holland B.V. Antigenic peptides of rabies virus and uses thereof
WO2006036410A2 (en) 2004-08-27 2006-04-06 The Regents Of The University Of California Protection from and treatment of prion protein infection
WO2006037038A1 (en) 2004-09-27 2006-04-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Optimized vaccines to provide protection against ebola and other viruses
PT1802336E (pt) 2004-10-14 2011-11-15 Glaxosmithkline Biolog Sa Vacinas de dose inicial/reforço para a malária
US8106170B2 (en) 2004-11-11 2012-01-31 Crucell Holland B.V. Compositions against SARS-coronavirus and uses thereof
SG159554A1 (en) 2004-11-16 2010-03-30 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
WO2006104678A2 (en) 2005-03-10 2006-10-05 The Regents Of The University Of California Identification of an evolutionarily conserved pathway mediating transrepression of inflammatory response genes by nuclear receptors
EP1984399A4 (en) 2006-02-10 2010-03-03 Univ California TRANSDUCIBLABLE DELIVERY OF SIRANA BY MEANS OF DSRNA BINDEDOMADE FUSIONS TO PTD / CPPS
WO2007110409A1 (en) 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
ES2635317T3 (es) * 2007-01-05 2017-10-03 University Of Zurich Anticuerpo anti-beta-amiloide y sus usos
EP2527369A3 (en) * 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
US20100093563A1 (en) 2008-09-22 2010-04-15 Robert Anthony Williamson Methods and vectors for display of molecules and displayed molecules and collections
WO2010033237A2 (en) 2008-09-22 2010-03-25 Calmune Corporation Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules
WO2010129033A2 (en) 2009-04-29 2010-11-11 Calmune Corporation Modified antibodies for passive immunotherapy
PT2248825E (pt) 2009-05-04 2013-01-07 Ribovax Biotechnologies Sa Fragmentos de antigénio ligantes a um anticorpo para uso no tratamento e diagnóstico de doenças oculares
US8748386B2 (en) * 2009-06-10 2014-06-10 New York University Immunological targeting of pathological Tau proteins
JP5762408B2 (ja) 2009-08-13 2015-08-12 クルセル ホランド ベー ヴェー ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法
JP5976541B2 (ja) 2009-09-17 2016-08-23 シーワイ オコーナー イレイド ヴィレッジ ファウンデーション 家畜のジェノタイピング方法
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
CN106188284B (zh) 2010-07-09 2020-05-08 扬森疫苗与预防公司 抗人呼吸道合胞病毒(rsv)抗体以及使用方法
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
US20130295021A1 (en) * 2010-10-11 2013-11-07 Feng Chen Human anti-tau antibodies
CN103370411B (zh) 2010-12-14 2016-05-04 美国卫生和人类服务部 腺病毒血清型26和血清型35线状病毒疫苗
EP2723377B1 (en) * 2011-06-22 2018-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
CN104185640B (zh) * 2011-09-19 2018-07-20 阿克松神经系统科学公司 阿尔茨海默病中的tau蛋白介导病变的基于蛋白质的疗法和诊断
CN104080806B (zh) * 2011-10-07 2018-01-19 Ac免疫有限公司 识别Tau的磷酸化特异抗体
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
MX357009B (es) 2011-11-28 2018-06-22 Crucell Holland Bv Vacunas contra el virus de la influenza y sus usos.
HUE045656T2 (hu) * 2011-12-20 2020-01-28 Janssen Biotech Inc PHF-tau elleni ellenanyagok és alkalmazásuk
US20130236494A1 (en) 2012-03-06 2013-09-12 Crucell Holland B.V. Vaccination against influenza
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
RU2668159C2 (ru) * 2012-07-03 2018-09-26 Вашингтон Юниверсити Антитела против тау
MX2015008024A (es) * 2012-12-21 2016-08-08 Biogen Int Neuroscience Gmbh Anticuerpos anti-tau humanos.
EP2986638A1 (en) 2013-04-15 2016-02-24 Crucell Holland B.V. Human antibodies binding to rsv g proteins
KR102201554B1 (ko) 2013-04-15 2021-01-12 얀센 백신스 앤드 프리벤션 비.브이. Ｒｓｖ ｇ 단백질에 결합하는 인간 항체
SG11201509663PA (en) 2013-05-30 2015-12-30 Crucell Holland Bv Influenza virus vaccines and uses thereof
WO2015197820A1 (en) 2014-06-26 2015-12-30 Crucell Holland B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau

Also Published As

Publication number Publication date
BR112016029579A2 (pt) 2017-08-22
WO2015197820A1 (en) 2015-12-30
SG11201610446XA (en) 2017-01-27
CA2952745A1 (en) 2015-12-30
WO2015197823A3 (en) 2016-02-18
CN107074935B (zh) 2021-08-03
SG11201610459XA (en) 2017-01-27
KR20170023151A (ko) 2017-03-02
EP3160998A1 (en) 2017-05-03
KR20170023124A (ko) 2017-03-02
EA201692539A1 (ru) 2017-04-28
EP3486256A2 (en) 2019-05-22
JP2017521063A (ja) 2017-08-03
EA035530B1 (ru) 2020-06-30
US10400034B2 (en) 2019-09-03
EP3160999B1 (en) 2018-11-28
AU2015279089B2 (en) 2021-01-28
EA036307B1 (ru) 2020-10-23
EP3160998B1 (en) 2019-08-21
NZ727020A (en) 2022-02-25
EA201692394A1 (ru) 2017-04-28
CA2952741A1 (en) 2015-12-30
CN107074965B (zh) 2021-08-03
US20170152307A1 (en) 2017-06-01
CN107074935A (zh) 2017-08-18
JP6641305B2 (ja) 2020-02-05
AU2015279089A1 (en) 2016-12-15
NZ727024A (en) 2022-02-25
US10301379B2 (en) 2019-05-28
ZA201608811B (en) 2022-09-28
CN107074965A (zh) 2017-08-18
EP3486256A3 (en) 2019-08-28
AU2015279086A1 (en) 2016-12-15
AU2015279086B2 (en) 2021-01-28
WO2015197823A2 (en) 2015-12-30
EP3160999A2 (en) 2017-05-03
US20170210787A1 (en) 2017-07-27
JP2017520254A (ja) 2017-07-27
AU2020294348A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
BR112016030183A2 (pt) anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos
CY1125011T1 (el) Ενεργοποιουμενα αντισωματα enanti-cd71 και μεθοδοι χρησης αυτων
ZA201700528B (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
PH12017502180A1 (en) Tau-binding antibodies
EA201792414A1 (ru) Антитела против cd166, активируемые антитела против cd166 и способы их применения
DK3182999T3 (da) Anti-lag3-antistoffer og antigenbindingsfragmenter
CU20170169A7 (es) Anticuerpos de factor xi
BR112018006251A2 (pt) anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
PH12017502207A1 (en) Tau-binding antibodies
MX2017006301A (es) Conjugados de anticuerpo- farmaco.
CR20150575A (es) Anticuerpos humanos pac1
EA202091350A1 (ru) Связывающие молекулы, специфично связывающиеся с тау-белком
EA201992281A1 (ru) Связывающие молекулы, специфично связывающиеся с тау-белком
DK3455261T3 (da) Anti-ror2-antistoffer, antistoffragmenter, immunkonjugater deraf og anvendelser deraf
EP3269735A4 (en) Anti-sclerostin antibody, antigen binding fragment and medical use thereof
ZA202001807B (en) Il-5 antibody, antigen binding fragment thereof, and medical application therefor
GB201614627D0 (en) Antigen binding proteins

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]